E-Cigarette ‘Deeming’ Rule In OMB Review As Health Groups Urge Claim Enforcement
This article was originally published in The Tan Sheet
Executive Summary
FDA’s proposed final rule to deem e-cigarettes and other novel products, cigars and pipe tobacco subject to its tobacco oversight is under OMB review. The American Cancer Society and other medical groups, meanwhile, urge immediate action against e-cigarette marketers making smoking cessation claims.
You may also be interested in...
With Deeming Rule Pending, FDA Reminds E-Cigarette Firms About Drug Claims
In a proposed rule, FDA describes to a new audience its long-established policy on drugs and devices marketed for off-label indications. The agency says “some ambiguity surrounds the circumstances” that determine whether a product is regulated as tobacco or as a drug, device or combination product
Turning Back Calendar Could Keep E-Cigarettes Available Without Approval
Exercising enforcement discretion concerning the grandfather date for e-cigarettes and other products covered in FDA’s proposed deeming rule would not be the agency’s first use of the enforcement tool in implementing Tobacco Control Act regulations.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.